Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:CVACNASDAQ:ELVNNASDAQ:FHTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.56-2.5%$2.59$0.80▼$4.08$934.98M0.853.19 million shs6.46 million shsCVACCureVac$5.57-0.5%$3.70$2.37▼$5.72$1.25B2.49801,626 shs4.83 million shsELVNEnliven Therapeutics$21.91+11.4%$18.18$13.30▼$30.03$1.08B0.79284,375 shs3.22 million shsFHTXFoghorn Therapeutics$4.32-4.8%$4.10$2.94▼$10.25$240.80M3.04129,634 shs67,542 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+2.24%-1.08%+47.18%+61.50%+214.66%CVACCureVac+37.59%+25.56%+65.19%+86.05%+34.94%ELVNEnliven Therapeutics+0.31%-8.00%-1.85%-5.21%-13.58%FHTXFoghorn Therapeutics-0.87%+10.19%+4.85%+2.48%-24.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.9728 of 5 stars3.62.00.04.02.80.80.6CVACCureVac4.3856 of 5 stars3.54.00.04.82.50.01.3ELVNEnliven Therapeutics2.5509 of 5 stars3.51.00.00.02.84.20.0FHTXFoghorn Therapeutics2.2023 of 5 stars3.62.00.00.01.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7589.61% UpsideCVACCureVac 2.67Moderate Buy$9.0061.58% UpsideELVNEnliven Therapeutics 3.00Buy$37.2570.01% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.13180.67% UpsideCurrent Analyst Ratings BreakdownLatest FHTX, AKBA, CVAC, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.005/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/30/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.004/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M5.06N/AN/A($0.16) per share-22.25CVACCureVac$523.70M2.39N/AN/A$2.50 per share2.23ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AFHTXFoghorn Therapeutics$23.50M10.25N/AN/A($1.83) per share-2.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/6/2025 (Estimated)CVACCureVac-$281.58M$0.9210.13N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)ELVNEnliven Therapeutics-$71.58M-$1.92N/AN/AN/AN/A-29.46%-27.33%8/12/2025 (Estimated)FHTXFoghorn Therapeutics-$98.43M-$1.36N/AN/AN/A-357.53%N/A-30.98%8/6/2025 (Estimated)Latest FHTX, AKBA, CVAC, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 million3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21CVACCureVac0.056.206.19ELVNEnliven TherapeuticsN/A17.4417.44FHTXFoghorn TherapeuticsN/A4.774.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CVACCureVac17.26%ELVNEnliven Therapeutics95.08%FHTXFoghorn Therapeutics61.55%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%CVACCureVac2.15%ELVNEnliven Therapeutics25.90%FHTXFoghorn Therapeutics7.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableCVACCureVac880224.34 million219.07 millionOptionableELVNEnliven Therapeutics5049.07 million34.59 millionOptionableFHTXFoghorn Therapeutics12055.74 million50.57 millionOptionableFHTX, AKBA, CVAC, and ELVN HeadlinesRecent News About These CompaniesAnalysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $12.13June 7, 2025 | americanbankingnews.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Buy" by BrokeragesJune 4, 2025 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Position Boosted by Point72 Asset Management L.P.May 23, 2025 | marketbeat.comFoghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025May 22, 2025 | quiverquant.comFoghorn Therapeutics to Participate in Four Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comQ2 EPS Estimate for Foghorn Therapeutics Cut by AnalystMay 20, 2025 | marketbeat.comWedbush Expects Weaker Earnings for Foghorn TherapeuticsMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX)May 19, 2025 | marketbeat.comFoghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2025 | zacks.comFoghorn Therapeutics Provides First Quarter 2025 Financial and Corporate UpdateMay 14, 2025 | globenewswire.comWhy Foghorn Therapeutics Inc.’s (FHTX) Stock Is Up 5.95%May 13, 2025 | aaii.comWhy Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 5.19%May 10, 2025 | aaii.comFoghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdlesMay 7, 2025 | investing.comWhy Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 8.12%May 7, 2025 | aaii.comFoghorn Therapeutics to Participate in the Citizens Life Sciences ConferenceMay 5, 2025 | globenewswire.comFoghorn Therapeutics expands board with biotech veteransMay 3, 2025 | investing.comFoghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of DirectorsMay 1, 2025 | globenewswire.comFoghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline UpdateApril 28, 2025 | globenewswire.comJMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform RecommendationApril 23, 2025 | msn.comFoghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual MeetingApril 15, 2025 | globenewswire.comFoghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC PatientsMarch 26, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFHTX, AKBA, CVAC, and ELVN Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.56 -0.09 (-2.47%) Closing price 04:00 PM EasternExtended Trading$3.55 -0.01 (-0.28%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CureVac NASDAQ:CVAC$5.57 -0.03 (-0.54%) Closing price 04:00 PM EasternExtended Trading$5.55 -0.02 (-0.36%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Enliven Therapeutics NASDAQ:ELVN$21.91 +2.25 (+11.44%) Closing price 04:00 PM EasternExtended Trading$21.96 +0.05 (+0.25%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Foghorn Therapeutics NASDAQ:FHTX$4.32 -0.22 (-4.85%) Closing price 04:00 PM EasternExtended Trading$4.32 +0.00 (+0.12%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
